Abstract
Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Anti-Cancer Agents in Medicinal Chemistry
Title: The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy
Volume: 11 Issue: 2
Author(s): Ludmil Benov, James Craik and Ines Batinic-Haberle
Affiliation:
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Abstract: Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Export Options
About this article
Cite this article as:
Benov Ludmil, Craik James and Batinic-Haberle Ines, The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152011795255975
DOI https://dx.doi.org/10.2174/187152011795255975 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Monocytes Mediate HIV Neuropathogenesis: Mechanisms that Contribute to HIV Associated Neurocognitive Disorders
Current HIV Research MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Carcinogenesis and Therapeutic Strategies in Thyroid Cancer
Current Drug Targets “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Mammaglobin-Based Strategies for Treatment of Breast Cancer
Current Cancer Drug Targets Immunosuppressive Therapy for Myelodysplastic Syndromes
Current Pharmaceutical Design MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Proliferative Activity Of Neokyotorphinrelated Hemoglobin Fragments In Cell Cultures
Protein & Peptide Letters Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer
Current Cancer Drug Targets Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Current Medicinal Chemistry Highly Active Antiretroviral Therapy is Associated with Improved Survival among Patients with AIDS-Related Primary Central Nervous System Non-Hodgkins Lymphoma
Current HIV Research Identification of Essential 2D and 3D Chemical Features for Discovery of the Novel Tubulin Polymerization Inhibitors
Current Topics in Medicinal Chemistry Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry L1 Retrotransposon and Retinoblastoma: Molecular Linkages Between Epigenetics and Cancer
Current Molecular Medicine Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Circulating MicroRNAs: Valuable Biomarkers for the Diagnosis and Prognosis of Gastric Cancer
Current Medicinal Chemistry Modulation of Protein-Protein Interactions by Stabilizing/Mimicking Protein Secondary Structure Elements
Current Topics in Medicinal Chemistry Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets